Skip to main content
    P

    Pelthos Therapeutics Inc. (PTHS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $6.89
    -0.26 (-3.64%)

    Market Cap: $28.10M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Pelthos Therapeutics Inc. (PTHS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Pelthos Therapeutics (PTHS) has a market cap of $28.10M and an enterprise value of $75.67M. Revenue grew 592.92% over the last 12 months from the 12 months before. It kept -152.16% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 169.24% above the market cap, as debt exceeds cash.

    Market Cap$28.10M
    Enterprise Value$75.67M
    Latest price (Nov 17, 2026)$6.89

    Key Dates

    The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 17, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 9.14% in the quarter ended Sep 30, 2026.

    Shares Outstanding3.86M
    Shares Change (YoY)+26.17%
    Shares Change (QoQ)+9.14%

    Valuation Ratios

    The price to sales ratio is 0.5x.

    P/S Ratio0.5x
    Forward P/S0.5x

    Price Statistics

    The stock is down 79.50% over 52 weeks and trades 60.54% below its 50-day average.

    Beta (1Y)1.01
    52-Week Change-79.50%
    1-Month Change-65.99%
    3-Month Change-73.32%
    6-Month Change-74.48%
    Total Return (1Y)-79.50%
    Return vs SPY (1Y)-89.91%
    Max Drawdown (1Y)-79.31%
    Max Drawdown (3Y)-88.73%
    Sharpe Ratio (1Y)-1.57
    Correlation with SPY (1Y)0.14
    50-Day Average$17.46
    200-Day Average$23.26
    52-Week Range$7.12 to $31.65
    RSI (14 Days)24.0
    Average Volume (20 Days)67.62K

    Price chart

    Financial Position

    Current assets cover 1.78x current liabilities.

    Current Ratio1.78x
    Quick Ratio1.10x
    Interest Coverage-7.37x

    Returns and Efficiency

    Return on invested capital is -95.44% over the last 12 months.

    Return on Assets (ROA)-60.59%
    Return on Invested Capital (ROIC)-95.44%
    Return on Capital Employed (ROCE)-63.03%
    Asset Turnover0.40x
    Inventory Turnover0.40x
    Receivables Turnover3.68x
    Cash Conversion Cycle806 days

    Scores

    PTHS has an Altman Z-Score of -2.14, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-2.14
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $51.29M over the last 12 months.

    Revenue$51.29M
    Revenue Growth (YoY)+592.92%
    Gross Profit$42.68M
    Operating Income-$52.11M
    Pretax Income-$84.97M
    Net Income-$78.05M
    EBIT-$61.38M
    Reported EPS (TTM)-$17.06

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$17.69M
    Total Debt$65.25M
    Net Debt$47.56M
    Net Debt Per Share$12.31
    Working Capital$24.63M
    Shareholder Equity-$6.19M
    Tangible Book Value-$67.21M
    Total Assets$128.82M
    Total Liabilities$135.00M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $355.00K of capital spending, operating cash flow left -$32.56M of free cash flow.

    Operating Cash Flow-$32.21M
    Capital Expenditures$355.00K
    Free Cash Flow-$32.56M
    FCF Per Share-$8.28
    Depreciation and Amortization$6.26M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -101.59%.

    Gross Margin83.20%
    Operating Margin-101.59%
    Pretax Margin-165.66%
    Net Margin-152.16%
    EBIT Margin-119.66%
    FCF Margin-63.48%

    Stock Splits

    The last split was a 1-for-10 reverse split on Jul 2, 2025.

    Last Split DateJul 2, 2025
    Split TypeReverse split
    Split Ratio1:10

    Peer Position

    Against 3 similar companies, PTHS has the lowest P/S.

    P/S Ratio0.5x vs 2.1x median
    ROIC-95.44% vs -170.49% median
    Revenue Growth (Trailing 4 Quarters, YoY)+592.92% vs -100.00% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About PTHS

    What is PTHS's market cap?

    Pelthos Therapeutics has a market cap of $28.10M. Its enterprise value, which adds debt and subtracts cash, is $75.67M.

    How many shares of PTHS are outstanding?

    Pelthos Therapeutics has 3.86M shares outstanding. The count is up 26.17% from a year earlier.

    Does PTHS pay a dividend?

    No. Pelthos Therapeutics does not pay a dividend.

    How much debt does PTHS have?

    Pelthos Therapeutics has $65.25M of total debt and $17.69M of cash and equivalents, a net debt position of $47.56M.